Salesforce Friends ...
Health Care: Drugs
Columbia Laboratories Inc. (CBRX: NASDAQ)
$0.68 0.00 | 0.00%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 4.50 | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.99 | 0.94 | 0.98 |
| Price to Sales (TTM) | 1.73 | 4.21 | 1.42 |
| Price to Book (MRQ) | 2.28 | 3.38 | 2.41 |
| Price to Tangible Book (MRQ) | 2.28 | -8.72 | 5.08 |
| Price to Cash Flow (TTM) | 2.20 | 274.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -60.10 | -63.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 23.61 | -0.76 |
| Payout Ratio (TTM) | 0.00 | n.a. | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -69.30 | 37.70 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -5.70 | 1.60 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 12.72 | 7.01 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -44.81 | 4.51 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 4.50 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 5.50 | 2.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.90 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.91 | 0.96 |
| Interest Coverage (TTM) | 3,248.00 | 0.70 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 66.50 | 54.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 79.60 | 54.70 | 47.70 |
| EBITD Margin (TTM) | 36.50 | 17.90 | 18.90 |
| EBITD - 5 Yr Avg | -21.59 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 77.60 | -1.60 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -28.50 | -1.20 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.78 | -0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -27.60 | -1.20 | 7.00 |
| Return on Assets (TTM) | 77.90 | -0.40 | 3.10 |
| Return on Assets - 5 Yr Avg | -24.30 | -0.60 | 2.50 |
| Return on Investment (TTM) | 102.00 | -0.60 | 7.90 |
| Return on Investment - 5 Yr Avg | -40.80 | -0.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 1,638,153.00 | 379,608.00 | 449,376.00 |
| Net Income/Employee (TTM) | 1,269,927.00 | -4,557.00 | 39,003.00 |
| Receivable Turnover (TTM) | 11.80 | 6.60 | 7.60 |
| Inventory Turnover (TTM) | 3.00 | 2.90 | 8.30 |
| Asset Turnover (TTM) | 1.10 | 0.50 | 0.40 |
Portfolios with CBRX
- Portfolio NameUser Type
- UserMy Portfolio
- Contributor11 Stocks Under $4 With Upside
- Usermincronn Portfolio 1
- Usercscob Portfolio 1
- Userpharmer
- UserSUPRATRADE 2307070204
- UserSUPRATRADE VIRTUAL SKY
- Userstock fund
- UserBob700 Portfolio 1
- UserDunroamins
Latest CBRX Headlines from TheStreet
- A Classic Biotech Long Shot 04.05.12 | 09:04 am
- Columbia Stock Gaps Down On Today's Open (CBRX) 02.27.12 | 08:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Columbia Stock Soars (CBRX) 01.24.12 | 12:01 pm
- Columbia Stock Gaps Down On Today's Open (CBRX) 01.23.12 | 08:01 am
- Columbia Stock Gaps Up On Today's Open (CBRX) 01.18.12 | 08:01 am
- Columbia Laboratories Inc. Stock Upgraded (CBRX) 08.10.11 | 07:08 am
- 11 Stocks Under $4 With Upside: Analysts 05.11.11 | 12:05 pm
- Biotech Calendar: Key Dates for May 05.02.11 | 09:05 am
- Columbia Stock Falls On Unusually High Volume (CBRX) 04.06.11 | 02:04 pm
Press Releases for CBRX
- Columbia Laboratories Reports First Quarter 2012 Financial Results - Business Wire 05.04.12 | 06:05 am
- Columbia Laboratories Hires Cowen And Company To Assist In Evaluating Potential Strategic Transactions - Business Wire 03.13.12 | 06:03 am
- Columbia Laboratories Reports Fourth Quarter And Year-End 2011 Financial Results - Business Wire 03.08.12 | 06:03 am
- Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter - Business Wire 03.06.12 | 04:03 pm
- Columbia Laboratories Announces 42% Workforce Reduction - Business Wire 03.01.12 | 04:03 pm
- Columbia Laboratories To Discuss Fourth Quarter And Year-End 2011 Financial Results On March 8, 2012, Conference Call - Business Wire 03.01.12 | 06:03 am
- Columbia Laboratories Will Present March 5th At Cowen And Company Health Care Conference - Business Wire 02.29.12 | 06:02 am
- Faruqi & Faruqi, LLP Announces Investigation Of Columbia Laboratories Inc. - PR Newswire 02.09.12 | 11:02 am
- The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Columbia Laboratories Inc. Of Class Action Lawsuit And The Deadline Of April 2, 2012 To Seek A Lead Plaintiff Position - Business Wire 02.02.12 | 02:02 pm
- Bronstein, Gewirtz & Grossman, LLC Investigates Columbia Laboratories, Inc. - Business Wire 01.23.12 | 10:01 am
Partner Headlines for CBRX
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Market Losers - Benzinga 01.23.12 | 01:01 pm
- Columbia Labs Plummet after Recommendation Denial by FDA - Benzinga 01.23.12 | 09:01 am
- FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length - Benzinga 01.20.12 | 04:01 pm
- Watson Pharma and Columbia Labs Plunge on Proposed FDA Review - Benzinga 01.17.12 | 01:01 pm
- Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA - Benzinga 11.10.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 09.16.11 | 09:09 am
- Watson to Market Antares' OAB Drug - Analyst Blog - Zacks 07.12.11 | 10:07 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
